Complications of combined treatment with deferiprone and desferrioxamine in thalassemic patients

Iranian Journal of Medical Sciences

Volumn 32, Issue 1, 2007, Pages 40-44

  Eshghi, Peyman ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Compliance; Deferiprone; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE;

ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; RECURRENT DISEASE; THALASSEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 34548819036     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program 2003; 40-61.
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen R. Complications of beta-thalassemia major in North America. Blood 2004; 104: 34-9.
3. Grady RW, Berdoukas V, Rachmilewitz EA, et al. Iron chelation therapy: metabolic aspects of combining deferiprone and deferoxamine. 11th International Conference on Oral Chelation in the Treatment of Thalassemia Major and Other Disease. Catania, Italy; 2001. p. 74-8.
4. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-4.
5. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassemia patients. Br J Haematol 2003; 121: 187-9.
6. Galanello R, Doneddu I, Dessi E, et al. Iron chelation in thalassemia major: combined treatment with deferiprone and deferoxamine. 11th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases. Catania, Italy; 2001. p. 73.
7. Balveer K, Pryar K, Wonke B. Combined oral and parenteral iron chelation in beta thalassemia major. Med J Malaysia 2001; 55: 493-7.
8. Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, et al. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica 2004; 89: ELT07.
9. Farmaki K, Anagnostopoulos G, Platis O, et al. Combined chelation therapy in patients with thalassemia major: a fast and effective method of reducing ferritin levels and cardiological complications. Hematol J 2002; 3: 79.
10. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol 2000; 108: 305-12.
11. Jensen PD, Jensen FT, Christensen T, et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003; 101: 91-6.
12. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330-6.
13. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91: 224-9.
14. Berkovitch M, Laxer R, Inman R, et al. Arthropathy in thalassemia patients receiving deferiprone. Lancet 1994; 343: 1471-2.
15. Breuer W, Ermers MJJ, Pootrakul P, et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 2001; 97: 792-8.
16. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol 2005; 74: 217-20.
17. Cermak J, Brabec V. Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone). Vnitr Lek 1994; 40: 586-90.
18. Davood-abai Farahani H, Eshghi P. Evaluation of compliance to iron chelation therapy with desferoxamine in major thalassemic children in Zahedan in 2001. 9th international Conference on Thalassemia and Hemoglobinopathy. October 15-19, Palermo, Italy; 2003. p. 164.